ArticleSurgical endoscopy2026
Minimally invasive vs. open-extended distal pancreatectomy with multi-organ resection: postoperative and oncological outcomes for left-sided pancreatic ductal adenocarcinoma.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMinimally invasive extended distal pancreatectomy (MIEDP) is often challenging for pancreatic ductal adenocarcinoma (PDAC) due to its aggressive invasion into adjacent organs or major blood vessels. This study aimed to compare the surgical and oncological outcomes of MIEDP and open-extended distal pancreatectomy (OEDP) for left-sided PDAC.
methodsA retrospective data review was conducted for 798 patients with left-sided PDAC who underwent distal pancreatectomy between 2009 and 2020. Among these, 388 patients were included in the analysis who underwent extended distal pancreatectomy, as defined in the Miami International evidence-based guidelines.
resultsOf those 388 included patients, 217 underwent MIEDP and 171 OEDP. No significant differences were observed in the clinicopathological characteristics or 90-day mortality rates between the groups. Moreover, severe complications (CDC III or higher) were similar between groups (MIEDP: 11.1%; OEDP: 17.6%; P = 0.052). MIEDP was associated with a shorter time to adjuvant chemotherapy initiation relative to OEDP (5.9 vs. 6.6 weeks; P = 0.061). Multivariable analysis revealed that combined vessel resection was a significant factor for severe complications (OR: 3.642, 95% CI: 2.025-6.549; P < 0.001). The five-year survival rates were comparable (MIEDP: 25.5%; OEDP: 18.1%; P = 0.132). However, poorer survival was associated with pathological invasion of adjacent organs (HR: 1.479, 95% CI: 1.133-1.930; P = 0.004), postoperative complications, R0 resection, poor differentiation, lymphovascular invasion, perineural invasion, and failure to complete adjuvant chemotherapy.
conclusionsMIEDP is feasible and safe in selected left-sided PDAC with suspected multiorgan invasion and shows oncologic outcomes comparable to OEDP, with faster recovery signals. Prognosis appears driven more by pathological invasion than by surgical approach or extent of concomitant resection.
Indexed as
Identifiers
41345530What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.